COMMUNIQUÉS West-GlobeNewswire

Milestone Scientific Announces Favorable Medicare Pricing for its CompuFlo® Epidural System within First JMAC Region Covering Florida
10/07/2024
Reports progress in reimbursement strategy with additional JMAC regions ROSELAND, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery [...]
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
10/07/2024
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applications Tevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility challenges ExacTcell’s first [...]
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii
10/07/2024
RECCE ® 327 (R327) demonstrated significant bactericidal activity against ‘superbug’ Acinetobacter baumannii ( A. baumannii ) demonstrating 99.99999% log reduction (>7.5 log reduction) in adult human epidermal ‘skin [...]
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
10/07/2024
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9 [...]
Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy
10/07/2024
TRX103 is designed to reset the immune system, improve clinical outcomes, and potentially cure patients suffering from autoimmune and inflammatory disorders This marks the first use of an allogeneic engineered Type 1 [...]
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
10/07/2024
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its [...]
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
10/07/2024
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July [...]
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
10/07/2024
Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a [...]
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
10/07/2024
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans following positive feedback from the FDA to move forward with [...]
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
10/07/2024
Phase 1 HELIOS study evaluates AXPAXLI™ for non-proliferative diabetic retinopathy (NPDR) BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a [...]
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
10/07/2024
Formulation designed to enhance brain uptake SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment [...]
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
10/07/2024
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti- [...]
Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
10/07/2024
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular [...]
EARLY WARNING NEWS RELEASE
10/07/2024
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, July 10, 2024 (GLOBE NEWSWIRE) -- This news release is being issued by 1480775 B.C. Ltd. (the " Purchaser "), as [...]
TerrAscend to Host Second Quarter 2024 Earnings Conference Call
10/07/2024
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that it will host a scheduled [...]
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
10/07/2024
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- [...]
ExactCare and Tabula Rasa HealthCare Rebrand Combined Organization as AnewHealth
10/07/2024
AnewHealth provides transformative pharmacy solutions that elevate care and help providers and payers overcome the unique challenges of caring for the most at-risk patients in healthcare CLEVELAND, OH and MOORESTOWN, NJ [...]
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
10/07/2024
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an [...]
Theratechnologies présente ses résultats financiers et annonce un bénéfice net positif pour le deuxième trimestre de l’exercice 2024
10/07/2024
Revenus de 22 millions de dollars au deuxième trimestre , en hausse de 25 % d’un exercice à l’autre Réalisation d’un bénéfice net ajusté de 1 million de dollars et d’un BAIIA ajusté 1 de 5,5 millions de dollars [...]

Pages